YD BIO LTD (YDES) Stock Price & Overview

NASDAQ:YDES • KYG983011076

Current stock price

6.26 USD
+0.48 (+8.3%)
Last:

The current stock price of YDES is 6.26 USD. Today YDES is up by 8.3%. In the past month the price decreased by -16.64%.

YDES Key Statistics

1-Month Range5.4 - 8.77
Current YDES stock price positioned within its 1-month range.
Market Cap
441.455M
P/E
N/A
Fwd P/E
N/A
EPS (TTM)
-0.02
Dividend Yield
N/A

YDES Stock Performance

Today
+8.3%
1 Week
-15.75%
1 Month
-16.64%
3 Months
-49.27%
Longer-term
6 Months -64.04%
1 Year N/A
2 Years N/A
3 Years N/A
5 Years N/A
10 Years N/A

YDES Stock Chart

YD BIO LTD / YDES Daily stock chart

YDES Technical Analysis

ChartMill assigns a technical rating of 0 / 10 to YDES.


Chartmill TA Rating
Chartmill Setup Rating

YDES Fundamental Analysis

ChartMill assigns a fundamental rating of 3 / 10 to YDES. While YDES seems to be doing ok healthwise, there are quite some concerns on its profitability.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

YDES Earnings

Next Earnings DateMay 4, 2026
Last Earnings DateFeb 16, 2026
PeriodQ2 / 2025
EPS Reported
Revenue Reported
EPS Surprise %
Revenue Surprise %

YDES Forecast & Estimates


Analysts
AnalystsN/A
Price TargetN/A
EPS Next YN/A
Revenue Next YearN/A

YDES Groups

Sector & Classification

Sub-Industry
Biotechnology
Index Membership

YDES Financial Highlights

Over the last trailing twelve months YDES reported a non-GAAP Earnings per Share(EPS) of -0.02. The EPS decreased by -10100% compared to the year before.


Income Statements
Revenue(TTM)510.40K
Net Income(TTM)-1.41M
Industry RankSector Rank
PM (TTM) N/A
ROA -24.17%
ROE -27.74%
Debt/Equity 0
Chartmill High Growth Momentum
EPS Q2Q%-1082.61%
Sales Q2Q%27.34%
EPS 1Y (TTM)-10100%
Revenue 1Y (TTM)45.79%

YDES Ownership

Ownership
Inst Owners0.47%
Shares70.52M
Float13.14M
Ins Owners77.13%
Short Float %0.27%
Short Ratio1.34

About YDES

Company Profile

YDES logo image YD Bio Ltd. engages in the development of detection and therapeutic technologies. The company is headquartered in Taipei City, Taipei and currently employs 5 full-time employees. The company went IPO on 2025-08-29. The firm is focused on blood-based cancer detection, the development of stem cell- and exosome-based therapeutics with the potential to transform the treatment of diseases with unmet medical need and serving as a trusted supplier of clinical testing drugs for pharmaceutical companies. The company is focused on advancing a diversified portfolio of healthcare solutions across oncology diagnostics, regenerative medicine and clinical trial support. The company is a supplier of clinical trial drugs and has expanded into the development and distribution of post-market auxiliary products. Its core programs include Blood-Based Cancer Detection, Stem Cell- and Exosome-Based Ophthalmology Therapies, and Clinical Trial and AncillaryServices. The company is developing proprietary DNA methylation-based detection technology for a range of cancers, which includes a screening test for the early detection of pancreatic cancer and a monitoring test for recurrent breast cancer.

Company Info

IPO: 2025-08-29

YD BIO LTD

12F, No. 3, Xingnan Street, Nangang District

Taipei City TAIPEI TW

Employees: 5

YDES Company Website

Phone: 88623820330

YD BIO LTD / YDES FAQ

What does YD BIO LTD do?

YD Bio Ltd. engages in the development of detection and therapeutic technologies. The company is headquartered in Taipei City, Taipei and currently employs 5 full-time employees. The company went IPO on 2025-08-29. The firm is focused on blood-based cancer detection, the development of stem cell- and exosome-based therapeutics with the potential to transform the treatment of diseases with unmet medical need and serving as a trusted supplier of clinical testing drugs for pharmaceutical companies. The company is focused on advancing a diversified portfolio of healthcare solutions across oncology diagnostics, regenerative medicine and clinical trial support. The company is a supplier of clinical trial drugs and has expanded into the development and distribution of post-market auxiliary products. Its core programs include Blood-Based Cancer Detection, Stem Cell- and Exosome-Based Ophthalmology Therapies, and Clinical Trial and AncillaryServices. The company is developing proprietary DNA methylation-based detection technology for a range of cancers, which includes a screening test for the early detection of pancreatic cancer and a monitoring test for recurrent breast cancer.


Can you provide the latest stock price for YD BIO LTD?

The current stock price of YDES is 6.26 USD. The price increased by 8.3% in the last trading session.


Does YDES stock pay dividends?

YDES does not pay a dividend.


What is the ChartMill technical and fundamental rating of YDES stock?

YDES has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 3 out of 10.


Should I buy YDES stock?

This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on YDES.


What is YD BIO LTD worth?

YD BIO LTD (YDES) has a market capitalization of 441.46M USD. This makes YDES a Small Cap stock.